PH12021550033A1 - Tumor reduction formulations and methods of use thereof - Google Patents

Tumor reduction formulations and methods of use thereof

Info

Publication number
PH12021550033A1
PH12021550033A1 PH12021550033A PH12021550033A PH12021550033A1 PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1 PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A PH12021550033 A PH 12021550033A PH 12021550033 A1 PH12021550033 A1 PH 12021550033A1
Authority
PH
Philippines
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
relates
Prior art date
Application number
PH12021550033A
Other languages
English (en)
Inventor
Steven Hoffman
John Rothman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of PH12021550033A1 publication Critical patent/PH12021550033A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PH12021550033A 2018-07-09 2021-01-06 Tumor reduction formulations and methods of use thereof PH12021550033A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12021550033A1 true PH12021550033A1 (en) 2021-09-20

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550033A PH12021550033A1 (en) 2018-07-09 2021-01-06 Tumor reduction formulations and methods of use thereof

Country Status (11)

Country Link
EP (1) EP3820482A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530482A (cg-RX-API-DMAC7.html)
KR (1) KR20220098082A (cg-RX-API-DMAC7.html)
CN (1) CN112584841A (cg-RX-API-DMAC7.html)
AU (1) AU2019309757A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000279A8 (cg-RX-API-DMAC7.html)
CA (1) CA3105717A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190201A1 (cg-RX-API-DMAC7.html)
IL (1) IL280000A (cg-RX-API-DMAC7.html)
PH (1) PH12021550033A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020023191A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186392A1 (zh) * 2019-03-15 2020-09-24 大连大学 甘氨胆酸在制备抗肿瘤药物中的应用
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
IL293706A (en) * 2019-12-09 2022-08-01 Tyme Inc Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060135729A (ko) * 2004-01-29 2006-12-29 백스터 인터내셔널 인코포레이티드 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
AU2015287749B2 (en) * 2014-07-11 2021-03-11 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
EA201892051A1 (ru) * 2016-03-15 2019-02-28 Тайм, Инк. Фармацевтические композиции для лечения злокачественного новообразования

Also Published As

Publication number Publication date
CA3105717A1 (en) 2020-01-30
BR112021000279A2 (pt) 2021-04-06
CN112584841A (zh) 2021-03-30
IL280000A (en) 2021-03-01
JP2021530482A (ja) 2021-11-11
KR20220098082A (ko) 2022-07-11
CN112584841A8 (zh) 2021-06-18
EP3820482A1 (en) 2021-05-19
EP3820482A4 (en) 2022-03-23
AU2019309757A1 (en) 2021-03-04
EA202190201A1 (ru) 2021-04-09
BR112021000279A8 (pt) 2021-04-20
WO2020023191A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2023010042A (es) Polinucleotidos moduladores.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
SG11202011589WA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
ZA202001756B (en) Oral care compositions
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2016130581A8 (en) Combination cancer therapy
EA202190201A1 (ru) Составы для уменьшения размера опухоли и способы их применения
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
IL272834A (en) Compositions of amantadine, their preparation, and methods of use
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
GB201915831D0 (en) Compounds, compositions and therapeutic uses thereof
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
MX2016012244A (es) Compuestos y sus metodos de uso.
GB201915829D0 (en) Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) Compounds, compositions and therapeutic uses thereof
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
PT4027976T (pt) Composições de rifabutina e método de produção